John Martin | CEO
John has been an Executive Director since 2009 and was appointed CEO in November 2014. John has over 20 years of experience as a business executive, director and corporate lawyer including roles as CEO and Director of ASX listed and private emerging technology companies including BTF and Proteome Systems. John was a corporate and executive partner of Allens specialising in M&A, fundraising and life sciences.
Professor Graham Vesey | Chief Scientific Officer
Graham is a co-founder and founding CEO of Regeneus and has served on the Board since incorporation. Graham was appointed Chief Scientific Officer in November 2014. Graham is a successful biotechnology entrepreneur, technology innovator and inventor and a highly regarded scientist. Graham was a co-founder and Executive Director of BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.
John Bird | Chief Financial Officer
John is the Chief Financial and Operations Officer. John joined Regeneus in 2014. He is an experienced CFO with over 25 years in senior finance and operations roles in technology, service and manufacturing organisations. John undertook his undergraduate studies while working as an auditor for KPMG and has subsequently gained a wealth of financial and operational experience in Australian and US private and listed companies including GE, AWA Ltd, TAB Ltd, Shufflemaster. John is a CPA with a Bachelor of Economics from Macquarie University and is a member of the Australian Institute of Company Directors.
Janet Wilson | Clinical Research Director
Janet is the Director of Clinical Research, responsible for all clinical and preclinical research for the human health clinical programs. Janet joined Regeneus in 2013. She brings more than 20 years clinical research experience in the pharmaceutical industry, working on the design, execution and analysis of all phases of trials, including first-in-human studies through to pivotal, multicentre global studies. She has extensive experience in clinical project management, including outsourcing and vendor management, in highly regulated and complex territories.
Dr Charlotte Morgan | Head of R&D
Charlotte is Head of Research and Development and Production. Charlotte joined Regeneus in 2012. She started her career in the UK as a research scientist in the water and microbiology industries. After a move to Australia, she completed a PhD in precise microbiological reference materials, and gained a position as R&D manager at BTF. Since joining Regeneus, the emphasis has been on animal and human cell therapy product development. Our research and development team are responsible for investigational product manufacture for all of our cell therapy product clinical trials and for our human cancer vaccine. They have manufactured investigational products for both animal and human trials.
Dr Duncan Thomson | VP Licensing and Alliances
Duncan is the Head of the Veterinary Business Unit. Duncan joined Regeneus in 2010. He is a qualified veterinarian, having practiced in Australia and the UK for 5 years before doing an MBA. Since then he worked in Novartis Animal Health, a pharmaceutical company, in Switzerland, USA and Australia in senior marketing, sales and managerial roles. He is responsible for the development of CryoShot and Kvax for entry into the veterinary market.
Sandra McIntosh | Company Secretary and Investor Relations
Sandra is the Company Secretary and is responsible for investor relations. Sandra joined the company in 2009. She brings more than 20 years management experience in HR, customer service and finance. Sandra previously worked at BTF where she was the Global Customer Service Manager. Sandra has successfully completed certificates of Applied Corporate Governance through Governance Institute of Australia and has an AIRA Diploma in Investor Relations.
Lucy Millican | Quality Manager
Lucy Millican joined Regeneus in 2011 having previously worked for BTF, also in the role of Quality Manager. Lucy has over 20 years experience in quality and risk management in business including the veterinary, medical and biotechnology sectors, successfully achieving accreditation where required. Lucy has an honours degree in Biology, is a qualified Lead Auditor, a JP, a member of the RQA (Research Quality Association) and holds Regulatory Affairs Certificate: Pharmaceuticals from RAPS (Regulatory Affairs Professional Society).